Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New antidepressant drugs.

Y D Lapierre

    The Journal of Clinical Psychiatry
    |August 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    New antidepressants are reviewed for their effects on neurotransmitter systems, dosages, side effects, and efficacy. This research aids depression treatment and understanding its underlying mechanisms.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Fluphenazine, trifluoperazine and perphenazine in Vacutainers.

    Canadian Medical Association journal·2010
    Same author

    What are the issues surrounding long-term benzodiazepine treatment for generalized anxiety disorder.

    Journal of psychiatry & neuroscience : JPN·2001
    Same author

    Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder.

    American journal of medical genetics·2000
    Same author

    Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia.

    Canadian journal of psychiatry. Revue canadienne de psychiatrie·1999
    Same author

    Obsessive-compulsive spectrum disorders: effective treatment with paroxetine.

    Canadian journal of psychiatry. Revue canadienne de psychiatrie·1999
    Same author

    Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression.

    Psychiatry research·1999
    Same journal

    Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

    The Journal of clinical psychiatry·2026
    Same journal

    Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

    The Journal of clinical psychiatry·2026
    Same journal

    Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

    The Journal of clinical psychiatry·2026
    Same journal

    Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

    The Journal of clinical psychiatry·2026
    Same journal

    Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

    The Journal of clinical psychiatry·2026
    Same journal

    The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

    The Journal of clinical psychiatry·2026
    See all related articles

    Area of Science:

    • Neuroscience
    • Pharmacology
    • Psychiatry

    Background:

    • Depression is a complex mood disorder with various underlying neurobiological mechanisms.
    • Current antidepressant therapies target specific neurotransmitter systems, but novel agents are continually being developed.

    Purpose of the Study:

    • To review recently marketed, investigational, and in-development antidepressants.
    • To analyze these agents based on their targeted neurotransmitter systems, dosage, side effect profiles, and comparative efficacy.

    Main Methods:

    • Literature review of recently marketed antidepressants.
    • Analysis of ongoing clinical trials and drugs in development.
    • Comparative assessment of efficacy, safety, and mechanism of action.

    Related Experiment Videos

    Main Results:

    • Identification of key neurotransmitter systems targeted by new antidepressants.
    • Summarization of typical dosage ranges and common side effect profiles.
    • Evaluation of comparative efficacy against existing treatments.

    Conclusions:

    • The development of novel antidepressants enhances treatment options for depression.
    • These new agents contribute to a deeper understanding of the neurobiological underpinnings of depression.